Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Hemoperfusion Abridged 17Apr2020
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Sedation abridged 15Apr2020 V1 CTL
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
RAS antagonists abridged 1MAY2020 V 2.0
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Leronlimab 29 abridged Apr 2020 Version 2 LR EB
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Anticoagulation Abridged 24APR2020 Version2 EOS JMA PPR
Emerging Infections
For any questions or information, please email covidrapidreviewteam@gmail.com.
IVIg Abridged V2 10July2020 Revised (1) – Copy
Emerging Infections
For any questions or information, please email covidrapidreviewteam@gmail.com.
Nitric Oxide_Abridged_11Apr_ver1_KLR,AFM
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Convalescent Plasma Abridged V4 13April 2020
Covid-PSMID
Emerging Infections
For any questions or information, please email covidrapidreviewteam@gmail.com.
Xray_Abridged V3 10Apr2020 TSJ IGC
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.